Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baum

Showing results (121-130 of 470) with videos related to

Pageof 47
Sort By:
The Histochemical Journal|December 1, 1994
Fixation requirements for the immunohistochemical reactivity of PCNA antibody PC10 on cryostat sectionsH P Baum, J Reichrath, A Theobald, et al.
Nuclear Medicine and Biology|July 2, 2011
Synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine based on a cartridge purification methodDirk Mueller, Ingo Klette, Fabrizia Kalb, et al.
Toxins|January 20, 2022
Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland RadioprotectionJoerg Mueller, Thomas Langbein, Aditi Mishra, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|September 9, 2010
Therapeutic nuclear medicine in pediatric malignancyM Schmidt, R P Baum, T Simon, et al.
Nuklearmedizin. Nuclear Medicine|October 31, 2006
[Unusual, unilateral metastasis of a prostate-carcinoma and palliative rhenium-186 pain-therapy]I Breidert-Backes, S Adams, R P Baum, et al.
Theranostics|April 21, 2020
Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with <sup>177</sup>Lu-PSMA radioligand therapyFinn Edler von Eyben, Harshad R Kulkarni, Richard P Baum
Clinical Nuclear Medicine|August 7, 2018
Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine NeoplasmJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Nuklearmedizin. Nuclear Medicine|August 1, 1993
[Diagnosis of thrombosis with a murine anti-thrombocyte antibody (99mTc-BW 4): initial clinical results]A Hertel, R P Baum, T Baew-Christow, et al.
Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|July 24, 2001
Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRIT Stuckensen, A F Kovács, S Adams, et al.
Clinical Nuclear Medicine|January 24, 2019
Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 TrialJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Pageof 47

Showing results (121-130 of 470) with videos related to

Sort By:
Pageof 47
The Histochemical Journal|December 1, 1994
Fixation requirements for the immunohistochemical reactivity of PCNA antibody PC10 on cryostat sectionsH P Baum, J Reichrath, A Theobald, et al.
Nuclear Medicine and Biology|July 2, 2011
Synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine based on a cartridge purification methodDirk Mueller, Ingo Klette, Fabrizia Kalb, et al.
Toxins|January 20, 2022
Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland RadioprotectionJoerg Mueller, Thomas Langbein, Aditi Mishra, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|September 9, 2010
Therapeutic nuclear medicine in pediatric malignancyM Schmidt, R P Baum, T Simon, et al.
Nuklearmedizin. Nuclear Medicine|October 31, 2006
[Unusual, unilateral metastasis of a prostate-carcinoma and palliative rhenium-186 pain-therapy]I Breidert-Backes, S Adams, R P Baum, et al.
Theranostics|April 21, 2020
Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with <sup>177</sup>Lu-PSMA radioligand therapyFinn Edler von Eyben, Harshad R Kulkarni, Richard P Baum
Clinical Nuclear Medicine|August 7, 2018
Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine NeoplasmJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Nuklearmedizin. Nuclear Medicine|August 1, 1993
[Diagnosis of thrombosis with a murine anti-thrombocyte antibody (99mTc-BW 4): initial clinical results]A Hertel, R P Baum, T Baew-Christow, et al.
Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|July 24, 2001
Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRIT Stuckensen, A F Kovács, S Adams, et al.
Clinical Nuclear Medicine|January 24, 2019
Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 TrialJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Pageof 47